



April 20, 2016

## Innoviva to Report First Quarter 2016 Financial Results on April 28

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/20/16 -- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the first quarter ended March 31, 2016 after market close on Thursday, April 28, 2016. Innoviva management will host a webcast and conference call at 5:00 p.m. EDT that day to discuss the financial results and provide a corporate update.

To participate in the live call by telephone, please dial (877) 808-4482 from the U.S., or (484) 480-9192 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at [www.inva.com](http://www.inva.com) and will be archived there for 30 days. A telephone replay of the call will be available by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers and entering the confirmation code 85804537.

### **About Innoviva**

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc. For more information, please visit Innoviva's website at [www.inva.com](http://www.inva.com).

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

(INVA-F)

### **Contact Information:**

Eric d'Esparbes  
Senior Vice President and Chief Financial Officer  
650-238-9640  
[investor.relations@thrxinc.com](mailto:investor.relations@thrxinc.com)

Source: Innoviva

News Provided by Acquire Media